Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol

BMC Pregnancy and Childbirth

Jeffrey S Robinson²  Pat Ashwood²  Chad C Andersen¹  Philippa F Middleton²  Jane E Harding³  Caroline A Crowther³ 

[1] Department of Perinatal Medicine, Women’s and Children’s Hospital, Adelaide, Australia;Australian Research Centre for Health of Women and Babies (ARCH), The Robinson Institute, Discipline of Obstetrics and Gynaecology, Women’s & Children’s Hospital, The University of Adelaide, 72 King William Road, North Adelaide, South Australia, 5006, Australia;Liggins Institute, The University of Auckland, Auckland, New Zealand

关键词: Neurosensory disability;    Randomised controlled trial;    Preterm birth;    Betamethasone;    Dexamethasone;    Antenatal corticosteroids;   

Others  :  1138046
DOI  :  10.1186/1471-2393-13-104

 received in 2013-02-27, accepted in 2013-04-16,  发布年份 2013

【 摘 要 】

Background

Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce childhood neurosensory disability, remaining safe into adulthood. However, it is unclear which corticosteroid is of greater benefit to mother and child.

This study aims to determine whether giving dexamethasone to women at risk of preterm birth at less than 34 weeks’ gestation increases the chance of their children surviving free of neurosensory disability at two years’ corrected age, compared with betamethasone.

Methods/Design

Design randomised, multicentre, placebo controlled trial.

Inclusion criteria women at risk of preterm birth at less than 34 weeks’ gestation with a singleton or twin pregnancy and no contraindications to the use of antenatal corticosteroids and who give informed consent.

Trial entry & randomisation at telephone randomisation eligible women will be randomly allocated to either the dexamethasone group or the betamethasone group, allocated a study number and corresponding treatment pack.

Study groups women in the dexamethasone group will be administered two syringes of 12 mg dexamethasone (dexamethasone sodium phosphate) and women in the betamethasone group will be administered two syringes of 11.4 mg betamethasone (Celestone Chronodose). Both study groups consist of intramuscular treatments 24 hours apart.

Primary study outcome death or any neurosensory disability measured in children at two years’ corrected age.

Sample size a sample size of 1449 children is required to detect either a decrease in death or any neurosensory disability from 27.0% to 20.1% with dexamethasone compared with betamethasone, or an increase from 27.0% to 34.5% (two-sided alpha 0.05, 80% power, 5% loss to follow up, design effect 1.2).

Discussion

This study will provide high-level evidence of direct relevance for clinical practice. If one drug clearly results in significantly fewer deaths and fewer disabled children then it should be used consistently in women at risk of preterm birth and would be of great importance to women at risk of preterm birth, their children, health services and communities.

Trial registration

Trial registration number:ACTRN12608000631303

【 授权许可】

   
2013 Crowther et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]ANZNN (Australian and New Zealand Neonatal Network: Report of the Australian and New Zealand Neonatal Network 2008 and 2009. Sydney: ANZNN; 2012.
• [2]Saigal S, Doyle LW: An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008, 371(9608):261-269.
• [3]Roberts D, Dalziel S: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Db Syst Rev 2006, (3):CD004454.
• [4]NIH Consensus Panel: Antenatal corticosteroids revisited. NIH Consens Statement 2000, 17(2):1-10.
• [5]Brownfoot FC, Crowther CA, Middleton P: Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Db Syst Rev 2008, (4):CD006764.
• [6]Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A, Harding JE: Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 2005, 365(9474):1856-1862.
• [7]American College of Obstetricians and Gynecologists: ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. Int J Gynaecol Obstet 2002, 78(1):95-97.
• [8]Royal College Of Obstetricians and Gyanecologists (RCOG): Antenatal corticosteroids to reduce respiratory distress syndrome. Volume 7. Edited by RCOG. London, UK: Royal College of Obstetricians and Gynaecologists (RCOG); 2004. p.(Green-top Guideline; no. 7)
• [9]NIH Consensus Panel: Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995, 273(5):413-418.
• [10]Saengwaree P, Liabsuetrakul T: Changing physicians’ practice on corticosteroids. J Med Assoc Thai 2005, 88:307-313.
• [11]Lee BH, Stoll BJ, McDonald SA, Higgins RD: Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006, 117(5):1503-1510.
• [12]Baud O, Foix-L’Helias L, Kaminski M, Audibert F, Jarreau P-H, Papiernik E, Huon C, Lepercq J, Dehan M, Lacaze-Masmonteil T: Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. New Engl J Med 1999, 341:1190-1196.
• [13]Jobe AH, Soll RF: Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004, 190(4):878-881.
• [14]Quinlivan JA, Evans SF, Dunlop SA, Beazley LD, Newnham JP: Use of corticosteroids by Australian obstetricians - a survey of clinical practice. Aust Nz J Obstet Gyn 1998, 38(1):1-7.
• [15]Crowley P: Prophylactic corticosteroids for preterm birth. Cochrane Db Syst Rev 2006, (3):CD000065.
• [16]Brocklehurst P, Gates S, McKenzie-McHarg K, Alfirevic Z, Chamberlain G: Are we prescribing multiple courses of antenatal corticosteroids? A survey of practice in the UK. Brit J Obstet Gynaec 1999, 106(9):977-979.
• [17]Wallace EM, Baker LS: Effect of antenatal betamethasone administration on placental vascular resistance. Lancet 1999, 353(9162):1404-1407.
• [18]Murphy DJ, Caukwell S, Joels LA, Wardle P: Cohort study of the neonatal outcome of twin pregnancies that were treated with prophylactic or rescue antenatal corticosteroids. Am J Obstet Gynecol 2002, 187(2):483-488.
• [19]Pattinson RC, Makin JD, Funk M, Delport SD, Macdonald AP, Norman K, Kirsten G, Stewart C, Woods D, Moller G, Dexiprom Study Group: The use of dexamethasone in women with preterm premature rupture of membranes. S Afr Med J 1999, 89(8):865-870.
• [20]Lee BH, Stoll BJ, McDonald SA, Higgins RD: Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 2008, 121(2):289-296.
• [21]Bar-Lev MR, Maayan-Metzger A, Matok I, Heyman Z, Sivan E, Kuint J: Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. Obstet Gynecol 2004, 104(3):484-488.
• [22]Feldman DM, Carbone J, Belden L, Borgida AF, Herson V: Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates. Am J Obstet Gynecol 2007, 197(3):284-281.
• [23]Baud O, Laudenbach V, Evrard P, Gressens P: Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001, 50(6):706-711.
• [24]Amorim MM, Santos LC, Faundes A: Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 1999, 180(5):1283-1288.
• [25]MacArthur BA, Howie RN, Dezoete JA, Elkins J: School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics 1982, 70(1):99-105.
• [26]Smolders-de Haas H, Neuvel J, Schmand B, Treffers PE, Koppe JG, Hoeks J: Physical development of children who were treated antenatally with corticosteroids: a 10-12-year follow-up. Pediatrics 1990, 86:65-70.
• [27]Collaborative Group of Antenatal Steroid Therapy: Effects of antenatal dexamethasone administration in the infant: long-term follow-up. J Pediatr 1984, 104(2):259-267.
• [28]Salokorpi T, Sajaniemi N, Hallback H, Kari A, Rita H, von Wendt L: Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatr 1997, 86(3):294-298.
• [29]Chen C, Wang K, Chang T, Chen C, Loo J: Effects of antenatal betamethasone and dexamethasone in preterm neonates. Taiwan J Obstet Gynecol 2005, 44(3):247-251.
• [30]Elimian A, Garry D, Figueroa R, Spitzer A, Wiencek V, Quirk JG: Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol 2007, 110(1):26-30.
• [31]Mulder EJ, Derks JB, Visser GH: Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997, 104(11):1239-1247.
• [32]Senat MV, Minoui S, Multon O, Fernandez H, Frydman R, Ville Y: Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998, 105(7):749-755.
• [33]Subtil D, Tiberghien P, Devos P, Therby D, Leclerc G, Vaast P, Puech F: Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: A randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol 2003, 188(2):524-531.
• [34]Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS, ACTORDS Study Group: Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006, 367(9526):1913-1919.
• [35]Crowther CA, Doyle LW, Haslam RR, Hiller JE, Harding JE, Robinson JS, ACTORDS Study Group: Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. New Engl J Med 2007, 357(12):1179-1189.
• [36]Crowther CA, McKinlay CJ, Middleton P, Harding JE: Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Db Syst Rev 2011, (4):CD003935.
• [37]Doyle LW, Victorian Infant Collaborative Study Group: Changing availability of neonatal intensive care for extremely low birthweight infants in Victoria over two decades. Med J Aust 2004, 181(3):136-139.
• [38]Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B: Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997, 39(4):214-223.
• [39]Bayley N: Bayley Scales of Infant and Toddler Development (Third Edition). San Antonio: Harcourt Assessment (PsychCorp); 2006.
• [40]Achenbach T: Manual for the Child Behaviour Checklist 2/3 1992 Profile. Burlington: VT; 1992.
• [41]Rosner B, Prineas RJ, Loggie JM, Daniels SR: Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 1993, 123(6):871-886.
• [42]Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK 1990. Arch Dis Child 1995, 73(1):17-24.
• [43]Laws P, Abeywardana S, Walker J, Sullivan EA: Australia’s mothers and babies 2005. Sydney: National Perinatal Statistics Unit; 2007.
• [44]Crowther CA, Hiller JE, Haslam RR, Robinson JS, Giles W, Gill A, Walters W, Rowley M, Evans C, ACTOBAT Study Group: Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease. Lancet 1995, 345(8954):877-882.